Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Nuttli

Pulmonary Disease Metairie, LA Medical Doctor

NPI 1356310783 CMS profile 60877

4200 Houma Blvd, Fl 3, Metairie, LA 70006

Open in the dashboard

General payments

$9,296

531 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Nuttli of Metairie, LA is reported in the CMS Open Payments database as having received $9,296 across 531 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,087 107
2024 General $1,242 71
2023 General $1,839 96
2022 General $1,470 83
2021 General $1,052 67
2020 General $729 47
2019 General $877 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Nuttli
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Thomas Nuttli were reported at $2,087. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Thomas Nuttli Pulmonary Disease median Middle half National median
2019 $877 $377 $109–$1,340 $163
2020 $729 $230 $56–$907 $114
2021 $1,052 $269 $68–$1,072 $132
2022 $1,470 $390 $100–$1,457 $149
2023 $1,839 $419 $114–$1,659 $160
2024 $1,242 $476 $123–$1,818 $164
2025 $2,087 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,416 113 payments
  2. GlaxoSmithKline, LLC. $2,398 186 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $822 48 payments
  4. Regeneron Healthcare Solutions, Inc. $575 30 payments
  5. Actelion Pharmaceuticals US, Inc. $437 19 payments
  6. Genzyme Corporation $341 16 payments
  7. Grifols USA, LLC $299 13 payments
  8. Mylan Specialty L.P. $263 15 payments
  9. Merck Sharp & Dohme Corporation $175 9 payments
  10. Baxter Healthcare $140 6 payments
  11. Other $1,430 76 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,283 530 payments
  2. Education $13 1 payment
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $1,640 125 payments
  2. FASENRA $829 37 payments
  3. TEZSPIRE $805 32 payments
  4. BREZTRI $644 15 payments
  5. AIRSUPRA $479 16 payments
  6. SPIRIVA RESPIMAT $447 31 payments
  7. DUPIXENT $418 21 payments
  8. OFEV $413 22 payments
  9. UPTRAVI $413 17 payments
  10. NUCALA $373 30 payments
  11. Other $4,451 248 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

2,517

Median for Pulmonary Disease: 936

Drug cost

$1,266,399

Median for Pulmonary Disease: $487,987

Branded share of claims

71%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 39 $430,744
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 475 $415,456
Breo Ellipta Fluticasone/Vilanterol Brand 180 $88,515
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 60 $59,606
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 69 $47,215
Eliquis Apixaban Brand 50 $45,214
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 78 $38,182
Arnuity Ellipta Fluticasone Furoate Brand 148 $32,236
Spiriva Respimat Tiotropium Bromide Brand 28 $19,881
Symbicort Budesonide/Formoterol Fumarate Brand 57 $18,411

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$61,272

Of which drugs: $2,097

Medicare patients

356

Average age 76

Services billed

1,073

229 women, 127 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 49%
Arthritis 49%
Ischemic heart disease 38%
Diabetes 29%
Chronic kidney disease 28%
Osteoporosis 25%
Atrial fibrillation 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $237
$237 475 —
DUPIXENT
  • GENZYME CORPORATION $103
  • Regeneron Healthcare Solutions, Inc. $83
$186 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $175
$175 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $90
  • Amgen Inc. $58
$148 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $106
$106 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

531 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record